Powell Adam W, Nagarajan Rajaram, Mays Wayne A, Chin Clifford, Knilans Timothy K, Knecht Sandra K, Amos Michelle A, Gerdes Yvette M, Ryan Thomas D
*Cincinnati Children's Hospital, Division of Pediatric Cardiology †Cincinnati Children's Hospital, Division of Oncology, Cincinnati, OH.
Am J Clin Oncol. 2018 Nov;41(11):1058-1061. doi: 10.1097/COC.0000000000000422.
The cardiopulmonary exercise test (CPET) is a valuable tool to assess cardiopulmonary exercise capacity in pediatric oncology patients after chemotherapy. In addition, few studies on the utility of submaximal testing have been performed, which could be important as some patients are unable to complete a maximal effort test secondary to deconditioning by both disease and treatment.
We performed a retrospective chart review of pediatric cancer patients exposed to chemotherapy from 1992 to 2013 who underwent CPET with cycle ergometry (n=27). The study patients were compared with age-matched, sex-matched, and size-matched normal controls. The submaximal measure recorded was the oxygen consumption (VO2)@respiratory exchange ratio (RER) 1.0 during a maximal effort test.
The chemotherapy group demonstrated significantly lower exercise time (9.2±3.6 vs. 11.4±3.8; P=0.008), total work capacity (4914.4±3290.3 vs. 7664.4±4289.5; P=0.004), systolic blood pressure at peak exercise (162.9±23.2 vs. 177.3±23.8; P=0.01), indexed peak VO2 (33.9±6.9 vs. 40.0±6.3; P=0.001), and indexed peak oxygen pulse (6.1±1.3 vs. 7.0±1.5; P=0.004)). For the submaximal outcome measured, 11/27 of the chemotherapy patients had VO2@RER 1.0 values <-2 SD from the mean compared with 0/27 control patients.
Pediatric patients exposed to chemotherapy have impaired cardiopulmonary exercise capacity. The VO2@RER 1.0 in chemotherapy patients suggests that this may be a reliable submaximal measure in this population.
This study demonstrates that the CPET can be used in pediatric cancer survivors with prior exposure to chemotherapy to demonstrate impaired cardiopulmonary exercise tolerance, which is demonstrated on submaximal and maximal effort testing.
心肺运动试验(CPET)是评估儿科肿瘤患者化疗后心肺运动能力的一项重要工具。此外,关于次极量测试效用的研究较少,而这可能具有重要意义,因为一些患者由于疾病和治疗导致身体机能下降,无法完成极量运动测试。
我们对1992年至2013年接受化疗并进行了踏车测力计CPET的儿科癌症患者进行了回顾性病历审查(n = 27)。将研究患者与年龄、性别和体型匹配的正常对照进行比较。记录的次极量指标是极量运动测试期间呼吸交换率(RER)为1.0时的耗氧量(VO₂)。
化疗组的运动时间显著缩短(9.2±3.6对11.4±3.8;P = 0.008),总工作能力降低(4914.4±3290.3对7664.4±4289.5;P = 0.004),运动高峰时的收缩压降低(162.9±23.2对177.3±23.8;P = 0.01),峰值VO₂指数降低(33.9±6.9对40.0±6.3;P = 0.001),峰值氧脉搏指数降低(6.1±1.3对7.0±1.5;P = 0.004)。对于所测量的次极量结果,27例化疗患者中有11例的VO₂@RER 1.0值比平均值低2个标准差以上,而27例对照患者中无此情况。
接受化疗的儿科患者心肺运动能力受损。化疗患者的VO₂@RER 1.0表明,这可能是该人群中一项可靠的次极量指标。
本研究表明,CPET可用于曾接受化疗的儿科癌症幸存者,以证明其心肺运动耐量受损,这在次极量和极量运动测试中均得到体现。